Related Experiment Video
Updated: Nov 9, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Sustained-release isosorbide mononitrate as adjuvant treatment in isolated systolic hypertension in the elderly
Daniel Abad Pérez1, Iluminada García Polo2, Francisco José Rodríguez Salvanés3
1Internal Medicine Department, University Hospital de Getafe, Carretera de Madrid-Toledo, Madrid, Spain. danielabadperez@hotmail.com.
Insights
Nitrate treatment did not significantly reduce pulse pressure or improve vascular function in elderly patients with isolated systolic hypertension. This study found no benefit of nitrates for this condition.
Area of Science:
- Cardiology
- Geriatrics
- Pharmacology
Background:
- Isolated systolic hypertension is common in the elderly and linked to arterial stiffness.
- Current antihypertensives do not address arterial stiffness, but nitrates may.
- Nitrates' effect on arterial stiffness in elderly hypertension requires investigation.
Purpose of the Study:
- To assess the effect of sustained-release isosorbide mononitrate on pulse pressure in elderly patients with uncontrolled isolated systolic hypertension.
- To evaluate the impact of nitrate treatment on vascular function in this population.
Main Methods:
- Phase III, randomized, multicenter, double-blind, placebo-controlled trial.
- 58 patients (≥65 years) with isolated systolic hypertension received isosorbide mononitrate or placebo for 12 weeks.
- Primary endpoint: change in clinical pulse pressure; secondary: vascular function parameters.
Main Results:
- No significant difference in pulse pressure decline between the nitrate group (5.28 mmHg) and placebo group (7.49 mmHg).
- No significant improvements observed in vascular function parameters or adverse events.
- Intention-to-treat analysis showed no statistically significant benefits.
Conclusions:
- Sustained-release isosorbide mononitrate did not demonstrate efficacy in reducing pulse pressure in elderly isolated systolic hypertension.
- Nitrate treatment did not improve vascular function in this patient group.
- Further research is needed to explore alternative treatments for arterial stiffness in elderly hypertension.
Abstract:
Hypertension is one of the main cardiovascular risk factors. In the elderly, the most common form is isolated systolic hypertension, a consequence of the increase in arterial stiffness. None of the antihypertensives currently used affects arterial stiffness, whereas nitrates seem to have an effect. The aim of this work was to assess their effect on elderly patients with uncontrolled isolated systolic hypertension, defined as systolic blood pressure over 140 mmHg and diastolic blood pressure under 90 mmHg. The present study is a phase III, randomized, multicenter, double-blind, placebo-controlled clinical trial, conducted at the University Hospital La Princesa in Madrid. Patients of both sexes, aged 65 years or older, with poorly controlled isolated systolic hypertension, were treated with 40-60 mg of sustained-release isosorbide mononitrate or matching placebo for 12 weeks. The main objective was to assess the effect on clinical pulse pressure (PP); in addition, its effect on vascular function was evaluated. Analysis was performed by intention to treat. The study was registered at the European Union Clinical Trials Register (EUDRACT 2012-002988-10) and was funded by the Spanish Ministry of Health. A total of 58 patients with an average age of 77 years were enrolled, 32 were treated with nitrate, and 26 with placebo. No significant differences were found either in PP decline (5.28 vs 7.49 mmHg, p = 0.79) or in other variables, including parameters of vascular function. There were no differences in adverse events. The results of this study have not confirmed the benefit of nitrate treatment in isolated systolic hypertension or the improvement of vascular function.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Vasodilators
Heart Failure V: Medical Management
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antihypertensive Drugs: Direct Renin Inhibitors
Drug Dosing: Geriatric Patients
